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Abstract (256 words) 
Background: Asymptomatic patients with coronary artery disease (CAD), hypertension and/or 
type-2 diabetes (T2DM) are at greater risk of developing heart failure (HF). Fibrosis, leading to 
myocardial and vascular dysfunction, might be an important pathway of progression. 
Aims: To investigate the effects of spironolactone on serum markers of collagen metabolism and 
on cardiovascular structure and function in people at risk of developing HF and potential 
interactions with a marker of fibrogenic activity, galectin-3.  
Methods: A prospective, randomised, open-label, blinded end-point (PROBE) trial comparing 
spironolactone (up to 50mg/day) and standard care over 9 months in people with clinical risk 
factors for developing HF, including hypertension, CAD and T2DM, and elevated plasma 
concentrations of NT-pro-BNP (125 to 1,000 ng/L) or BNP (35 to 280 ng/L). Exclusion criteria 
included left ventricular ejection fraction (LVEF)<45%, atrial fibrillation, severe renal 
dysfunction or treatment with loop diuretics. The primary endpoint was the interaction between 
change in serum concentrations of procollagen type III N-terminal propeptide (PIIINP) and 
treatment with spironolactone according to median plasma concentrations of galectin-3 at 
baseline. 
Results: For the 527 participants enrolled, median (inter-quartile range) age was 73 (69-79) 
years, 135 (26%) were women, 412 (78%) had hypertension, 377 (72%) CAD and 212 (40%) 
T2DM. At baseline, medians (IQR) were for LVEF 63 (58-67) %, for left atrial volume index 31 
(26-37)mL/m2, for plasma NT-proBNP 214 (137-356) ng/L, for  serum PIIINP 3.9 (3.1- 
5.0) ng/mL and for galectin-3 16.1 (13.5-19.7) ng/mL. 
Conclusions: The HOMAGE trial will provide insights on the effect of spironolactone on 
pathways that might drive progression to HF.  
(NCT: 02556450; European Commission 7th Framework Programme; Grant Agreement n. 305507). 





Despite advances in care, the prognosis of heart failure is generally poor once it is clinically 
obvious (1). Changes to lifestyle and treating modifiable risk factors, such as hypertension, 
hyperlipidaemia and diabetes, may have delayed the onset of heart failure but have not reduced 
the life-time risk. Only a few trials have specifically investigated interventions to delay or 
prevent the onset of heart failure (2). Population screening, using blood tests or cardiac imaging, 
for early identification or prevention of heart failure has not yet been widely adopted, but there is 
a growing body of evidence, especially for natriuretic peptides, that such an approach might be 
useful (3,4). Pharmacological approaches to prevention might be most efficient when targeted at 
those both at greater risk and most likely to respond to a specific intervention. Markers of 
activity of pathways driving disease progression might provide such mechanistic biotargets, 
thereby providing a precision- or personalised-medicine approach.  
 
Natriuretic peptides are released by the heart in response to cardiovascular stress. About 10% of 
adults have increased plasma concentrations of natriuretic peptides (5), the proportion increasing 
with age and the development cardiovascular disease (6-9). Elevated plasma concentrations are 
associated with an increase in cardiovascular morbidity and mortality, including heart failure, 
whether or not the individual has clinically overt disease. Accordingly, low plasma 
concentrations of natriuretic peptides can be used to avoid unnecessary investigation and high 
concentrations used to target those in need of further investigation and treatment to delay or 
prevent the onset of clinically overt heart failure (4).  
 
Fibrosis of the myocardium, vasculature and kidney and possibly other organs might be a key 
pathway of progression from asymptomatic cardiac dysfunction to heart failure (10) and 
therefore a therapeutic biotarget. Accordingly, markers of collagen synthesis and degradation 
might identify patients more likely to respond to an intervention targeting fibrosis.  




Rationale for the trial 
Serum concentrations of procollagen type I C-terminal propeptide (PICP) and procollagen type 
III N-terminal propeptide (PIIINP), indicating increased synthesis of type-1 and type-3 collagen, 
are increased in HF, regardless of LVEF, and are associated with a worse prognosis (11-13). 
Serum PICP correlates directly with plasma concentrations of NT-proBNP and left atrial volume 
suggesting it is influenced by the degree of congestion (14). Increased serum concentrations of 
PIIINP in people without established CV disease are also associated with a higher risk of 
developing heart failure and of death (15, 16). An increase in Type-I collagen predominates in 
the failing heart, contributing to increased myocardial stiffness (17). Serum concentrations of 
collagen type I C-terminal telopeptide (CITP), indicating increased degradation of Type-1 
collagen, are also increased in heart failure (13) and associated with an adverse prognosis. 
Raised plasma concentrations of galectin-3, a marker of inflammation involved in aldosterone-
mediated fibrogenesis (18, 19), also predict incident heart failure in the general population (20).  
 
Altogether, these findings suggest that there is both increased synthesis and degradation of 
collagen in heart failure and that high collagen turnover is associated with an adverse outcome. 
Serum markers of collagen metabolism are also associated with an increase in myocardial 
extracellular matrix and therefore, presumably, collagen mass (11, 13, 21). It is likely that the 
pro-fibrotic state is systemic, with most collagen turnover occurring in organs such as bone-
marrow and liver, but with the consequences expressed selectively by organs subject to dynamic 
change, such as the heart and blood vessels. Accordingly, serum markers reflecting collagen 
metabolism might be used to select patients more likely to benefit from anti-fibrotic 
interventions for the prevention of heart failure and might also be used as surrogate markers of a 
therapeutic effect.  
 




Aldosterone plays an important role in regulating renal sodium and potassium exchange, plasma 
volume and systemic blood pressure. Experimental evidence also suggests that MRA have 
favourable effects on collagen metabolism (22). Randomised trials show that MRA are effective 
anti-hypertensive agents and reduce morbidity and mortality for patients with heart failure and a 
reduced (HFrEF) and, perhaps, mid-range (HFmrEF) or even preserved left ventricular ejection 
fraction (LVEF) (23-25). These benefits of MRA may be mediated through diuresis, potassium 
retention, autonomic effects and reduction in pre- and after-load. However, clinical trials in 
patients with either HFrEF or HFpEF also suggest that administration of an MRA often exerts 
changes in serum concentrations of markers of collagen turnover in a pattern favouring reduced 
synthesis (26). This may reflect both direct, systemic effects of MRA on collagen metabolism 
and the effects of MRA on pre- and after-load that may specifically prevent, retard or reverse 
myocardial, vascular and renal fibrosis.   
 
Effect of Spironolactone on Serum Markers of Collagen Metabolism in Clinical Trials 
(Table 1) 
The Randomized Aldactone Evaluation Study (RALES), a placebo-controlled trial of 
spironolactone in HFrEF, measured serum concentrations of collagen metabolism in a subgroup 
of 261 patients. Higher serum concentrations of PIIINP were associated with greater morbidity 
and mortality and, compared to placebo, treatment with spironolactone reduced serum PIIINP. 
Amongst patients with a serum PIIINP below median, spironolactone did not reduce death or the 
composite of hospitalisation and death but exerted a substantial effect on both endpoints amongst 
those with greater than median serum PIIINP (27). However, there were too few patients in to 
provide robust evidence of an interaction. Similar patterns were observed for PINP and PICP. 
Subsequently, other trials have variably confirmed (28, 29) or refuted (30) these results. Women 
and those with lower serum potassium concentrations, which might be associated with higher 
plasma concentrations of aldosterone, had a greater reduction in PIIINP following treatment with 




eplerenone in one trial (31).  Smaller trials of HFpEF have also shown conflicting results (14, 32, 
33).  Trials of patients with obesity and/ or hypertension have more consistently shown 
reductions in both PIIINP and PICP, as well as improvement in Doppler indices of diastolic LV 
dysfunction. (34-36). Overall, the trials suggest that MRA lead to more consistent reductions in 
serum PIIINP than PICP, markers of synthesis, with little effect on CITP, a marker of collagen 
degradation. 
 
The above observations provide the rationale for the « Heart OMics in AGing » (HOMAGE) trial, 
investigating whether spironolactone favourably alters markers of extra-cellular matrix 
remodelling for patients at increased risk of developing heart failure. The trial (clinicaltrials.gov: 
NCT02556450, EudraCT-No.: 2015-000413-48) was funded by the European Commission under 
the Health Cooperation Work Programme of the 7th Framework Programme, under the Grant 
Agreement n. 305507.  
 
 
Design of the trial 
HOMAGE is a multicentre, proof of concept, prospective, randomised, open-label, blinded end-
point (PROBE) trial in patients at high risk of developing heart failure, comparing 
spironolactone titrated to a target dose of 50mg/day compared to no additional treatment. The 
primary endpoint is the interaction between changes in serum concentrations of PIIINP from 
baseline to nine months and baseline plasma concentrations of galectin-3 in participants assigned 
to spironolactone or not. The trial was conducted in ten centres in six European Countries: 
France (Nancy, Corbeil-Essonnes and Toulouse), Italy (Cortona), United Kingdom (Kingston 
upon Hull, Manchester and Glasgow), The Netherlands (Maastricht), Germany (Berlin) and 
Ireland (Dublin). The protocol was approved by the institutional review board or the independent 




ethics committee for each institution before trial initiation. All patients provided written 
informed consent before participating in the trial. 
 
Inclusion and Exclusion Criteria (Table 2) 
People aged older than 65 years (later amended to >60 years) with established coronary artery 
disease or at least two criteria indicating CV disease (T2DM, hypertension, microalbuminuria, or 
an abnormal ECG) were invited to participate. Patients with a pre-existing diagnosis of heart 
failure or an LVEF <45% or currently treated with a loop diuretic were excluded. Patients with 
atrial fibrillation or severe renal dysfunction were excluded, as these conditions may cause 
increased plasma concentrations of natriuretic peptides without other evidence of CV disease. 
MRA are contraindicated in severe renal dysfunction or hyperkalaemia (>5.0mmol/L) and 
therefore such patients were excluded. 
 
At screening, after giving informed consent in writing, a blood test was taken and plasma 
concentrations of NT-proBNP or BNP measured in local-site laboratories. Plasma concentrations 
of NT-pro-BNP had to be in the ‘window’ between 125 and 1,000 ng/L or BNP between 35 and 
280 ng/ml. The lower boundary for plasma natriuretic peptide concentration was based on ESC 
guidelines for the exclusion of heart failure in the presence of symptoms and signs suggesting 
such a diagnosis (37). The upper boundary of the ‘window’ was introduced in order to exclude 
patients who had a high probability of serious, undiagnosed cardiac or renal disease who 
required further investigation and treatment rather than participation in this trial. 
 
Although people with an LVEF <45% or with moderate or severe valve disease were excluded, 
those with left ventricular hypertrophy or diastolic left ventricular dysfunction were not. 
Accordingly, patients enrolled in HOMAGE could have cardiac dysfunction on imaging and 
increased plasma concentrations of natriuretic peptides, thereby fulfilling two of the three 




diagnostic criteria for heart failure according to ESC guidelines, and for stage B heart failure in 
the ACC/AHA guidelines (37, 38).  
 
 
Randomization and Blinding 
Patients were randomised in a 1:1 ratio to spironolactone or control using random permuted 
blocks stratified by centre. Randomisation lists for each centre were created by the trial 
coordinating centre in Leuven, using the statistical software SAS 9.4. Randomisation was carried 
out via a web-based management system. All persons evaluating key tests, the clinical endpoints 
committee, and central laboratories were kept blind to treatment allocation. 
 
Trial Assessments (Figure 1) 
Patients were screened in primary and secondary care. All patients provided informed consent in 
writing before undergoing any research related procedures. The first patient was randomised in 
February 2016. The plan was to randomise 800 patients by the end of 2017 and follow all 
patients for nine months, completing the trial by a grant-deadline of November 2018. Due to 
slow recruitment rate, the trial steering committee extended the enrolment period until June 2018 
and reduced the minimum period of follow-up to 3 months. Eventually, 877 patients were 
screened, of whom 527 were randomised. (Figure 2) 
   
Major visits: baseline, one month and end of trial.    
Three major visits are planned, at baseline (randomisation), one month and nine months 
(modified to a minimum of 3 months for patients enrolled after January 2018). The one-month 
visit was designed to investigate short-term effects of spironolactone that might be attributed to 
direct effects on fluid and electrolyte balance and the later visit to investigate longer-term effects 
on cardiovascular structure and function.  





At these visits, patients completed quality of life (EQ5D) and symptom questionnaires 
(appendix) and blood for local and central laboratory analysis is collected, and an ECG and 
echocardiogram done. Echocardiograms were analysed, blind to allocation, in a core lab located 
in Nancy (France). Participants also did incremental shuttle walk-tests (ISWT), using a 10m 
course (the ‘shuttle) marked by two cones. The walking speed is determined by bleeps played 
from a compact disc: after every minute, walking speed is increased. There are up to 12 levels of 
speed and, potentially, 102 shuttles. Changes of 50-70 metres (5-7 shuttles) are considered 
clinically meaningful (39). Blood pressure was measured at the end of ISWT. During and after 
the ISWT, in a subgroup of participants, heart and respiratory rate were measured with a chest-
worn sensor (Equivital  Inc, New York, USA) or heart sounds measured via acoustic 
cardiography (Audicor, Inovise Medical, Inc., Portland, USA).  
 
Minor Follow-up visits: 7 days, three and six months of follow-up.   
The protocol required at least three additional visits, on Day 7 and at 3 and 6 months, when 
serum potassium and creatinine is measured in order to adjust the dose of spironolactone (Table 
3) and to ascertain adverse events.  
 
Assays 
Assays were done in a central laboratory. Plasma concentrations of galectin-3 were measured 
using an enzyme-linked immunosorbent assay (BG Medicine). Serum PIIINP and CITP were 
measured using a radio-immunoassay (Orion Diagnostica) and serum PICP using an enzyme 
immune-assay (Quidel Corp). Plasma NT-proBNP was measured using the Roche Elecsys assay 
(Roche Diagnostics GmbH, Mannheim, Germany).  
 
Trial End-points 





The hypothesis was that the effects of spironolactone on serum concentrations of collagen 
markers would be greater in patients with increased plasma concentrations of galectin-3, a 
marker of aldosterone-mediated, fibrotic activity. The primary endpoint was the interaction 
between baseline plasma concentration of galectin-3 and the effect of randomised treatment 
(MRA or control) on changes, from baseline to nine months, in serum concentrations of PIIINP. 
 
Secondary endpoints 
Secondary endpoints will be assessed both at one and nine months and will include other 
biomarkers of extracellular matrix turnover, PICP (synthesis) and CITP (degradation). We will 
also assess the effects of spironolactone on weight, serum electrolytes, blood pressure, renal 
function, symptoms, quality of life, exercise capacity and cardiac function, assessed by 
echocardiography, and plasma concentrations of NT-proBNP and galectin-3. In addition, new 
onset atrial fibrillation, heart failure and other serious adverse events will be assessed. 
 
Sample Size Calculation 
The trial sample size was determined based on the ability to detect a difference of 0.79μg/l in the 
change in PIIINP amongst participants assigned to spironolactone or control with a baseline 
plasma galectin-3 above or below the median value using a two-sided significance level of 5% 
and 90% power and a standard deviation estimated at 1.73μg/l (35). The original calculation 
required 800 participants, with >700 having evaluable serum PIIINP data but, as only 527 
patients were randomised, the trial has less power than originally conceived. Nonetheless, a trial 
of 500 patients provides 80% power to detect an interaction of 0.87μg/l in PIIINP with a two-
sided significance level of 5% (or 90% power to detect an interaction of 1.0μg/l in PIIINP). 
Thus, the trial has sufficient power to provide estimates of the likely effect-size and interaction 
effects between 0.87 and 1.0μg/l. Further statistical power may be gained through the method of 




analysis in the final analysis plan, in particular by treating galectin-3 as a continuous variable 
and using methods for measurements from several time-points. No interim efficacy analyses 
were planned or done. 
 
Statistical Analysis 
Statistical analyses will be carried out using Stata ® version 15.1. Baseline characteristics are 
presented as median and inter-quartile range for continuous variables and frequencies and 
percentages for categorical. The primary efficacy analyses will be carried out on the Full 
Analysis Set, defined as all randomized patients who received at least one dose of the trial 
medication. Analysis will be conducted according to the intention to treat principle.  
 
Analysis of the primary end-point will be carried out using analysis of covariance (ANCOVA). 
A linear regression model will be fitted, including a binary variable to indicate the treatment 
group, a binary variable to indicate galectin-3 above or below the median and baseline PIIINP. 
An interaction term will be included to evaluate the impact of spironolactone in those with 
galectin-3 above median. Residual analysis will be used to examine the fit of the model to the 
assumptions of linear regression and data may be transformed to meet the assumptions of linear 
regression. Sensitivity analyses will be carried out using multiple imputation with chained 
equations to impute missing baseline and/or final visit values. As this is a proof of concept trial, 
additional exploratory analyses may be carried out for the primary outcome, if appropriate, as 
pre-specified in a statistical analysis plan. There are no planned adjustments for multiple 
comparisons due to the exploratory nature of this trial. 
 
Baseline Characteristics 
The median (IQR) age of participants in the HOMAGE trial was 73 (69-79) years and a high 
proportion were men (74%), perhaps reflecting the use of CAD as a screening strategy (72%). 




Most participants (78%) had treated hypertension, but the median systolic blood pressure at entry 
was still 140mmHg and 25% had a systolic blood pressure exceeding 154mmHg. Most patients 
had stage II chronic kidney disease (eGFR 60-89 ml/min/1.73m2 ) and 40% had T2DM (Table 4) 
Median LVEF was normal at 63% (IQR 58-67%) and median plasma concentrations of NT-
proBNP were 214 (IQR: 137-356) ng/L (Table 5). Left atrial volume and the ratio of E/E’ were 
increased and left ventricular mass was at the upper limit of normal. On a symptom 
questionnaire (appendix), the median score in response to the question “do you get breathless on 
moderate exertion (eg:- walking quickly, climbing 2-3 flights of  stairs)” the median score was 5 
(2 - 6) indicating that most participants found this amount of exertion troublesome. Baseline 
serum concentrations of collagen markers were similar to those observed in previous trials of 
hypertension and heart failure. 
 
Potential impact 
As life expectancy increases, so will the prevalence of heart failure (40). Preventing or delaying 
the onset of heart failure could prolong active life and potentially reduce healthcare costs. Some 
treatments for hypertension can delay or prevent the development of heart failure in older people, 
but not all anti-hypertensive agents are similarly beneficial (41-43). Spironolactone has been 
used to treat patients since 1959. Its side effects are well-known, reversible and, at the doses used 
in this trial, usually not severe. It is a highly effective treatment for resistant hypertension (44), 
and is known to reduce morbidity and mortality for HFrEF. MRA also appear to have favourable 
effects on myocardial fibrosis, which might be a key pathway for the development of heart 
failure in general, and perhaps specifically HFpEF. 
 
Targeting specific mechanistic pathways involved in the progression to heart failure may 
increase the efficiency, safety and cost-effectiveness of pharmacological interventions for the 
prevention of heart failure. Patients with a biomarker profile suggesting increased fibrotic 




activity might receive greater benefit from an agent directed at fibrosis, such as an MRA. 
Targeting treatment at those who have more to gain could also avoid treating those with a less 
favourable benefit/risk profile.   
 
The HOMAGE trial enrolled people with few symptoms to suggest heart failure but with 
moderately elevated plasma concentrations of natriuretic peptides and a high prevalence of atrial 
dilation and left ventricular hypertrophy suggesting diastolic dysfunction. Indeed, patients 
enrolled in HOMAGE had higher plasma concentrations of NT-proBNP and greater left atrial 
dilatation than those enrolled in the ALDO-DHF (45) (Table 5), a trial of spironolactone in 
patients with symptomatic HFpEF. The patients in HOMAGE could be considered to have a 
“pre-HFpEF” syndrome. However, participants did report, on average, troublesome 
breathlessness on moderate exertion and therefore others might consider the patients already to 
have HFpEF.  However, plasma concentrations of NT-proBNP were somewhat lower than in 
large clinical outcome trials of HFpEF, such as PEP-CHF (46), PARAGON-HF (47) or 
TOPCAT (48) (Table 5), which generally required patients to have symptoms of congestion 
treated with diuretics, prior hospitalisations for heart failure, echocardiographic evidence of LV 
disease or left atrial dilation in addition to high plasma concentrations of natriuretic peptides. 
 
Trials of HFpEF have failed to show conclusive benefit, especially when those with HFmrEF are 
excluded. It is unclear whether women and men with HFpEF respond differently to treatments. 
In PARAGON-HF women may have responded better (47). In TOPCAT, the overall effect was 
similar for men and women, but this masked a greater benefit for men with an LVEF <50% but a 
higher risk if LVEF was >65%, whereas woman obtained little or no benefit throughout the 
range of measured LVEF (25). Patients with advanced disease may be less likely to respond to 
interventions. In a post-hoc analysis of the I-PRESERVE trial (49), for patients with HFpEF who 
had NT-proBNP below the median value (339ng/L), irbesartan reduced mortality by 25% and 




heart failure hospitalisation or death by 40%   (both statistically significant) but had no benefit 
for patients with higher NT-proBNP values who were at greater risk. This suggests that whilst 
patients with less severe diastolic dysfunction may be at lower risk that are also more amenable 
to treatment. Further credence to this hypothesis comes from the HYVET trial, which showed 
that a combination of indapamide and perindopril administered to elderly patients with poorly 
controlled hypertension had a striking reduction in heart failure events and mortality (41). Many 
of these patients must have had left ventricular hypertrophy, dilated left atria, raised natriuretic 
peptides and, had they been assessed carefully, symptoms and signs of heart failure; in other 
words HFpEF. These considerations suggest that an effective method for the management of 
HFpEF might be early detection and treatment to delay or prevent progression to the more severe 
manifestations of this condition. Those with advanced disease may be recalcitrant to therapy.  
 
Conclusions 
HOMAGE is a proof-of-concept trial that should be a catalyst for further research on biomarkers 
that might also be biotargets that indicate activation of specific, modifiable pathological 
pathways. This research approach may help deliver precision-medicine for personalised care. 
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Trial RALES27 AREA-in-CHF30 EPHESUS28 PARADIGM-HF55 
Population HFrEF HFrEF AMI complicated by HFrEF HFrEF 
Treatment Spironolactone vs. Placebo Canrenone vs. Placebo  Eplerenone vs. Placebo Sac./Val. vs. Enalapril (E) 
N= 261 382 476 2067 
Follow-up 6 months 6 months (12m for echo) Up to 9 months 8 months 
 Controls MRA Controls MRA Controls MRA Enalapril Sac/Val 
PIIINP - µg/L - pre 4.9 (2.5) 4.9 (2.7) 5.4 (4.0-7.4) 5.3 (3.9-6.9) 4.2 (1.5) 4.2 (1.7) 4.6 (3.6-5.9) 
PIIINP - µg/L – post 5.0 (2.8) 4.0 (1.9) Δ:+5.0% Δ:+3.7% 4.5 (6M) 4.0 (6M)~ -1.7% -4.5% 
 Δ: 0.11 Δ:-0.87*~   4.3 (9M) 3.7 (9M)~ Sac/Val vs E: -3% (p=0.086) 
PINP - µg/L - pre 51 (57) 41 (23) NR NR 35 (17) 33 (14) 36 (27–48) 
PINP - µg/L - post 57 (76) 36 (18) NR NR 44 (6M) 38 (6M)~ +0.6% -6.2% 
 Δ:6 Δ:-5*~   44 (9M) 36 (9M)~ Sac/Val vs E: -6% (p<0.001) 
CITP - µg/L - pre NR NR NR NR 6.7 (4.0) 6.4 (3.4) NR NR 
CITP - µg/L - post NR NR NR NR 5.3 (6M) 5.0 (6M) NR NR 
     5.3 (6M) 4.6 (9M) NR NR 
PICP - µg/L - pre 129 (47) 139 (117) NR NR NR NR NR NR 
PICP - µg/L - post 142 (79) 131 (113) NR NR NR NR NR NR 
 Δ:13 Δ:-8       
LAD – cm – pre NR NR 4.1 (0.6) 4.2 (0.8) NR NR NR NR 
LAD – cm – post NR NR 4.1 (0.7) 4.1 (0.8)~ NR NR NR NR 
LAVI – ml/m2 NR NR NR NR NR NR NR NR 
Doppler NR NR NR NR NR NR NR NR 
 
Trial PARAMOUNT 53,54  NCT0050533632 RAAM-PEF33 ALDO-DHF14,45 
Population HFpEF HFpEF HFpEF HFpEF 
Treatment  Valsartan vs Sac/Val Eplerenone vs. Placebo Eplerenone vs. Placebo Spironolactone vs. Placebo 
N= 301 44 44 381 
Follow-up 36 weeks Up to 12 months (M) Up to 26 weeks (W) 1 year 
 Valsartan  Sac/Val Controls MRA Controls MRA Controls MRA 
PIIINP - µg/L - pre 5.6 (4.3–6.8) 5.5 (4.4–7.2) 5.0 (2.0) 6.2 (3.3) 6.3 (5.2-8.9) 6.0 (4.3-10.1) NR NR 
PIIINP - µg/L – post 5.4 (4.1–7.0) 5.3 (4.2–7.2) 4.7 (3.3) (6M) 5.1 (2.1) (6M)* 6.2 (5.0-9.6) (W14) 4.7 (3.8-8.9) (W14)*~ NR NR 
   7.3 (4.0) (12M) *~ 5.7 (3.1) (12M) 5.9 (4.3-8.7) (W26) 5.8 (4.2-11.5) (W26) NR NR 
PINP - µg/L - pre NR NR 40 (17) 42 (21) 41 (29-60) 39 (26-66) NR NR 
PINP - µg/L - post NR NR 31 (16)* (6M) 32 (17)* (6M) 45 (35-61)(W14)* 31 (25-56) (W14)~ NR NR 
 NR NR 48 (20)* (12M) 43 (14) (12M) 43 (35-61) (W26) 30 (22-52)(W26)*~ NR NR 
CITP - µg/L - pre NR NR 5.8 (2.9) 6.7 (3.7) 6.0 (4.0-9.6) 5.8 (4.2-11.5) NR NR 
CITP - µg/L - post NR NR 5.7 (2.6) (6M) 6.8 (2.8) (6M) 5.7 (4.7-9.3) (W14) 6.4 (3.8-9.1) NR NR 
 NR NR 6.6 (4.2) (6M) 6.1 (3.4) (12M) 6.5 (4.8-8.7) (W26) 5.5 (4.3-8.9)~   
PICP - µg/L - pre NR NR 400 (107)# 415 (133)# 949 (652-1365)# 913 (708-1107)# 108 (88-129) 104 (81-129) 
PICP - µg/L - post NR NR 383 (99) (6M)# 399 (152) (6M)# 1081 (691-1325) (W14)# 793 (670-1086) (W14)# Δ 0.95 (0.91 to 0.99) (p=0.050) 
 NR NR 402 (104) (12M)# 425 (109) (12M)# 959 (781-1291) (W26)# 821 (673-1195) (W26)#   
LAD – cm – pre 3.7 (0.5) 3.7 (0.5) NR NR NR NR NR NR 
LAD – cm – post Δ: -0.08  Δ:-0.15* NR NR NR NR NR NR 
LAVI – ml/m2 - pre 36.3 (14.7) 35.2 (12.3) 45 (12) 50 (17) 80 (24)** 73 (26) 27.8 (26.9-28.6) 27.4 (26.6-28.2) 
LAVI – ml/m2 - post Δ:0.3 Δ:-2.6* 44 (14) (6M) 49 (20) (6M) 74 (23) (26W) 64 (23) (26W)* Δ -0.33 (-1.48 to 0.82) (p=0.58) 
   53 (23) (12M) 52 (19) (12M)     
Doppler No changes E’ decreased 6/12M* E’ decreased 12M* MRA improved E/E’~ MRA improved septal E’ and LVMi~ 
 
Trial REMINDER29 ASCOT36 ACTRN1260900065524634 NA35 
Population STEMI without HF Hypertension Obesity Metabolic syndrome 
Treatment Eplerenone vs. Placebo Spironolactone Spironolactone vs. Placebo Spironolactone vs. Placebo 
N= 526 146 113 80 
Follow-up 6 months 9 months 6 months 6 months 
 Controls MRA Matched Cohort MRA Controls MRA Controls MRA 
PIIINP - µg/L - pre 4.0 (3.3-4.6) 3.9 (3.2-4.7) 4.5 (3.7–6.3) 5.1 (3.6–6.4) 5.2(2.0) 5.2(2.0) 5.3 (1.9) 5.8 (2.0) 
PIIINP - µg/L – post Δ 0.5±1.4 Δ 0.2±1.5 Δ: 0.5 Δ:−0.4~ 5.4(2.9) 4.7 (1.9)*~ 5.2 (2.0) 4.9 (1.7)*~ 
         
PINP - µg/L - pre 29 (22-42) 32 (23-44) NR NR NR NR NR NR 
PINP - µg/L - post Δ 2.1±15.4 Δ -1.5±14.6~ NR NR NR NR NR NR 
         
CITP - µg/L - pre 3.8 (2.9-4.6) 3.7 (3.0-4.5) 5.9 (3.3–9.1) 7.1 (4.4–8.9) NR NR NR NR 
CITP - µg/L - post Δ 0.2±1.4 Δ 0.13±1.46 Δ: −1.2 Δ: −0.0 NR NR NR NR 
         
PICP - µg/L - pre NR NR 76 (63–90) 80 (66–102) 184 (75) 175 (76) 150 (44) 142 (33) 
PICP - µg/L - post NR NR Δ: 5 Δ :−6~ 190 (79) 146 (71)*~ 146 (47) 122 (23)*~ 
 NR NR       
LAD – cm – pre NR NR NR NR 4.3(0.4) 4.4(0.5) 4.3 (0.4) 4.4 (0.3) 
LAD – cm – post NR NR NR NR 4.3(0.4) 4.2(0.4)*~ 4.3 (0.5) 4.3 (0.3)* 
LAVI – ml/m2 NR NR NR NR NR NR NR NR 
Doppler NR NR NR NR MRA improved E/E’ & GLS’*~ MRA improved E/E’ & GLS’*~ 
 
Table 1. RCTs of mineralo-corticoid receptor antagonists (MRA) investigating effects on serum collagen-derived markers, in patients with Heart Failure and Reduced (HFrEF; 
top panel) or Preserved (HFpEF; mid panel) Left Ventricular Ejection Fraction, and in those at high risk of developing heart failure (lower panel). Data for two trials of 
sacubitril/valsartan are also shown. Data are reported as median (Interquartile range) or mean (Standard deviation), when available. *Indicates significant changes during 
follow-up within same arm (p<0.05). ~Indicates significant changes during follow-up between the two arms (p<0.05). Δ: change from baseline, or between arms; cells with 
significant differences are also shaded for ease of reading;  ** not indexed; # these values are extremely high, and higher than what has been reported in other studies, 
which is likely to reflect differences in kits and methods used to measure biomarker circulating levels.  
Abbreviations used: Procollagen type I C-terminal propeptide – PICP; Procollagen type III N-terminal propeptide – PIIINP; Collagen type I C-terminal telopeptide – CITP; N-
terminal propeptide of collagen I – PINP.  Left atrium – LA; Left atrial volume indexed – LAVI; Not reported – NR; Global longitudinal strain – GLS. 
Inclusion criteria Exclusion criteria 
1.Ability to provide written informed consent prior to any study procedure  
2. Age >65years (modified to >60 years during the trial) 
3. Clinical risk factors for developing heart failure, either:  
 
A. Coronary artery disease (h/o myocardial infarction, angioplasty or 
coronary artery bypass)  
Or 
B. At least two of the following:  
• Diabetes Mellitus requiring Hypoglycaemic Pharmacotherapy  
• Receiving pharmacological treatment for Hypertension  
• Microalbuminuria  
• Abnormal ECG (left ventricular hypertrophy, QRS >120msec,  
abnormal Q-waves)  
 
4. Biological risk: NT-pro-BNP values between 125 and 1,000 ng/L or BNP 
values between 35 and 280 pg/ml    
1. Recent wound healing/inflammation: 
• Surgical procedure, coronary, cerebral or peripheral vascular events or 
infection in the prior 3 months  
• Cancer (life limiting or less than 2 years in remission)  
• Autoimmune disease  
• Hepatic Disease  
2. Pre-existing diagnosis of clinical HF  
3. Moderate/severe LV systolic ventricular dysfunction, i.e. LVEF <45%  
4. Moderate or severe valve disease (investigators opinion)  
5. Corrected eGFR< 30ml/min/1.73m2, using the MDRD four-variable 
equation  
6. Serum potassium >5.0 mmol/L and serum sodium <125 mmol/L  
7. Treatment with an MRA or a loop diuretic (furosemide, bumetanide, 
ethacrynic acid or torasemide) in the previous three months  
8. Potassium supplements or potassium-sparing diuretic at time of 
enrolment.  
9. Atrial fibrillation within one month prior to inclusion  
10. History of hypersensitivity to spironolactone or to any of its excipients  
11.Patients who require treatment with prohibited medications according to 
the summary of product characteristics with the exception of ACE inhibitors 
or angiotensin receptor blockers – although not their combination  
12. Patients unable to give written informed consent  
13. Participation in another interventional trial in the preceding month  
14. Ability to walk is, in the investigators opinion, clearly limited by joint 
disease or other locomotor problems or lung diseases rather than by 
cardiorespiratory fitness  
Table 2. Main inclusion and exclusion criteria. 





25 mg OD to 50 mg OD  
25 mg EOD to 25 mg OD  




No dose adjustment  
 




50 mg OD to 25 mg OD  
25 mg OD to 25 mg EOD  
25 mg EOD to withhold  







Table 3. Dose adjustments after initiation of spironolactone treatment. Abbreviations used: EOD: Every Other Day; OD: Once daily. After 
withholding spironolactone due to high serum potassium, it can be re-started at a dose of 25 mg EOD when potassium levels have fallen below 
4.5 mmol/L. Spironolactone must be discontinued if serum creatinine ≥220 μmol/L (or eGFR ≤30 ml/min/1.73m2). Treatment may be restarted 
at the investigator's discretion once serum creatinine is <220 μmol/L and eGFR >30 ml/min/1.73m2. 
Table 4 
  Not Randomised Randomised 
  N=350 N=527 
Demographics and Lifestyle 
Age-years 70(67-75) 73(69-79) 
Female-N.(%) 70 (20) 135 (26) 
Caucasian-N.(%) 346 (99) 518 (98) 
Current smoker-N.(%) 39(11) 44(8) 
Inclusion Criteria  
CAD-N.(%) 249(71) 377(72) 
Diabetes-N.(%) 131(37) 212(40) 
Hypertension-N.(%) 280(80) 412(78) 
Micro albuminuria-N.(%) 79(23) 108(21) 
Abnormal ECG*-N.(%) 83(24) 176(33) 
Exclusion Criteria 
BNP/NT-ProBNP -N.(%) 253(72)  
LV systolic dysfunction-N.(%) 13(4) 
Valve disease-N.(%) 5(1) 
eGFR<30ml/min-N.(%) 2(<1) 
Serum potassium >5.0 mmol/L-N.(%) 9(3) 
MRA or loop diuretic treatment-N.(%) 7(2) 
Potassium supplements-N.(%) 3(<1) 
Atrial fibrillation-N.(%) 16(5) 
Confounding Medical Condition – N (%) 13(4) 
Other – N (%) 29(8) 
Medical History 
Myocardial Infarction-N.(%) 136(39) 214(41) 
PCI-N.(%) 176(50) 265(50) 
CABG-N.(%) 72(21) 136(26) 
Stroke/TIA-N.(%) 14(4) 28(5) 
COPD-N.(%) 23(7) 33(6) 
Pacemaker-N.(%) 12(3) 22(4) 
Medications 
Thiazide-N.(%) 50(14) 85(16) 
Beta Blocker-N.(%) 203(58) 365(69) 
ACE-I-N.(%) 175(50) 275(52) 
ARB-N.(%) 89(25) 145(28) 
CCB-N.(%) 58(17) 108(21) 
Statin/Lipid lowering drug-N.(%) 280(80) 431(82) 
Anticoagulant-N.(%) 27(8) 29(6) 
Aspirin-N.(%) 210(60) 373(71) 
Other Antiplatelet -N.(%) 58(17) 99(19) 
Anthropometrics 
Weight-kg 84 (75-95) 82 (72-92) 
BMI-kg/m2 28.5 (26.2-31.3) 28.1 (25.4-31.6) 
Waist-Hip ratio 0.98 (0.94-1.02) 0.98 (0.94-1.02) 
Symptoms & Vital Signs 
Systolic Blood Pressure-mmHg 141 (130-153) 140 (128-154) 
Diastolic Blood Pressure-mmHg 80 (74-87) 78 (71-85) 
Heart Rate-bpm 64 (58-71) 61 (55-67) 
NYHA I-N.(%) 279(80) 433(82) 
NYHA II-N.(%) 56(16) 76(14) 
NYHA III-N.(%) 6(2) 9(2) 
NYHA – Not done-N.(%) 9(3) 9(2) 
Blood Results 
eGFR- ml/min/1.73m2 77 (65-91) 72 (62-85) 
Haemoglobin-g/dl 14.4 (13.4-15.2) 14.0 (13.1-14.9) 
Creatinine-mg/dl 0.9 (0.8-1.1) 1.0 (0.8-1.1) 
Sodium-mmol/l 139 (137-141) 140 (138-141) 
Potassium-mmol/l 4.3 (4.0-4.5) 4.3 (4.1-4.6) 
EQ5D & HOMAGE symptoms questionnaire 
Visual Analogue Score 80 (65-90) 80 (70-90) 
Breathlessness on moderate exercise 3 (2-6) 5 (2-6) 
Swollen ankles 0 (0-1) 0 (0-2) 
Tiredness 2 (0-5) 3 (0-5) 
 
Table 4. Baseline characteristics of participants who were randomised or not in the 
HOMAGE trial. Abbreviations used: CAD – Coronary artery Disease; PCI - Percutaneous 
Coronary Intervention; CABG – Coronary Artery Bypass Grafting; TIA -  Transient 
Ischaemic Attack; COPD - Chronic Obstructive Pulmonary Disease; ACE-I -Angiotensin-
converting enzyme  inhibitors; ARB - Angiotensin receptor blockers ; CCB - Calcium 
channel blockers; MRA- mineralocorticoid receptor antagonist; eGFR - Estimated glomerular 
filtration rate; BMI- Body Mass Index; NYHA - New York Heart Association; LV – Left 
Ventricular; EQ5D - EuroQol-5D.  * Includes: Left Ventricular Hypertrophy, QRS 






HOMAGE* I-PRESERVE51 CHARMES52 PEP-CHF46 PARAMOUNT53,54 PARAGON-
HF47~ 
TOPCAT48^ 
Population No DD / DD HFpEF Hypertension At risk of HF HFpEF HFpEF HFpEF‡ HFpEF HFpEF HFpEF 
n =  600 / 182 422 173 527 4,133 109∏ 375 149 to Sac/Val 4,822 3,445 
Age – Years 46 / 64 67 (8) 64 (8) 73 (69-79) 72 65 ~77 71 73 (8) 69 (61-76) 
Men (%) 50 /43 48 80 74 40 65 45 43 48 48 
h/o CAD (%) NR 40 Excluded 72 48 76 25” 21 43 59 
h/o HTN (%) 30 / 81 92 100 78 88 69 73 95 96 91 
h/o T2DM (%) 1 / 3 17 46 40 27 26 21 41 43 32 
h/o AF (%) NR 5 NR Excluded 29 16 20 27 32 35 
SBP –mmHg 125 / 142 135 (18) 167 (19) 140 (128-154) 136 134 (19) ~138 136 131 (15) 130 (120-140) 
Diuretic (%) 5 / 25**** 54** 41 (Thz) LD Excluded 52 67** 53 (LD) 100 96# 82** 
eGFR ml/min/1.73m2  83 / 72 79 (19) 70 (62-77) 72 (62-85) 72 NR 52@ 67 (19) 63 (19) 68 (20) 


















LVEF - % NR 67 (8) NA 63 (58-67) 64 (9) ~50 63 58 58 (8) 60 (56-64) 
LAVI – mL/m2 22 / 27 28 (8) NR 31 (26-37) NR ~40 NR 35 NR 28 (21-35) 
LA Diameter - mm NR NR NR 46 (41-50) NR NR 45 (41-48) 37 NR 42 (38-47) 
E/E’ 6.4 / 9.3 12.8 (4.0) NR 9.4 (7.5-11.8) 10 (5) NR NR 12.4 NR 10.5 (L)/14.7 (S) 
LVMI – g/m2 88 / 105 109 (28) NR 95 (81-113) 164 (48)@ ~235@ NR 78 NR 108 (90-128) 
Collagen Biomarkers 
PIIINP – µg/L 4.5 / 5.6 NR 4.9 (3.7–6.3) 3.9 (3.1-5.0) 4.3 (3.7-5.4) NR NR 5.6 (4.3–6.9) NR Uncertain 
PICP – µg/L 100 / 103 111 (92-136) 78 (66–100) 81 (67-98) NR NR NR NR NR 130 (94-170) 
CITP – µg/L 5.3 / 6.3 NR 6.4 (4.2–8.8) 3.8 (2.9-5.1) NR NR NR NR NR Uncertain 
Gal-3 – µg/L 10.9 (9.0-13.1)∆ 12.5 (3.8) NR 16.1 (13.5-19.7) NR NR NR 17.8 (14.1–22.8) NR 19.2 (15.2-23.5) 
 
Table 5. Selection of trials, ranked by plasma NT-proBNP concentration conducted in patients with hypertension, at high risk of developing heart failure (HF), or 
with heart failure and preserved ejection fraction (HFpEF) showing clinical and echo data and, where available, serum collagen markers at baseline. Flemish 
population data is shown for reference. * At screening; **Did not distinguish between different classes of diuretics; ***Available for a subset only,∏ - excludes 
patients with moderate or severe diastolic grade 38% of whom had a h/o AF; ∏∏ - mean and standard deviation of patients reported to have normal or mild diastolic 
dysfunction and predominantly in sinus rhythm; # of which 26% were mineralocorticoid receptor antagonists; ~ required recent heart failure hospitalisation (within 9 
months from screening) or elevated NT-proBNP (>300 ng/L if sinus rhythm, > 900 ng/L if atrial fibrillation) as inclusion criteria; ^  required recent heart failure 
hospitalisation (within 12 months from screening) or elevated BNP (>100 ng/L) or NT-proBNP (>360 ng/L) as inclusion criteria; “ history of myocardial infarction; 
@ creatinine clearance (Cockcroft-Gault). ‡ - only cohort with NT-proBNP measured 
∆ = data taken from the PREVEND study in Netherlands population mean age 50 years (56).**** LD (%): 0.2/2.2; @not indexed. 
Abbreviations used: NR = not reported; h/o – history of; CAD – Coronary Artery Disease; HTN – Hypertension; T2DM – Type II Diabetes Mellitus; AF – Atrial 
Fibrillation; SBP – Systolic Blood Pressure; eGFR -Estimated glomerular filtration rate; LVEF – Left Ventricular Ejection Fraction; Thz = thiazide or thiazide-like 
diuretic; LD = loop diuretic 
Some data has been reported in abstract from for TOPCAT but vales for PIIINP and CITP appear highly inconsistent with ranges in published literature and some of 
the changes reported implausible. 
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